Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Operating Expenses (2018 - 2025)

Historic Operating Expenses for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $1.2 million.

  • BioNexus Gene Lab's Operating Expenses fell 4421.93% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 31482.95%. This contributed to the annual value of -$4.9 million for FY2024, which is 1194.28% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Operating Expenses stood at $1.2 million, which was down 4421.93% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Operating Expenses registered a high of $6.2 million during Q3 2023, and its lowest value of -$8.5 million during Q4 2024.
  • In the last 5 years, BioNexus Gene Lab's Operating Expenses had a median value of $797910.0 in 2021 and averaged $313964.5.
  • Within the past 5 years, the most significant YoY rise in BioNexus Gene Lab's Operating Expenses was 63590.05% (2023), while the steepest drop was 50651.62% (2023).
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Operating Expenses stood at $365662.0 in 2021, then surged by 166.84% to $975716.0 in 2022, then crashed by 506.52% to -$4.0 million in 2023, then tumbled by 113.57% to -$8.5 million in 2024, then surged by 114.02% to $1.2 million in 2025.
  • Its Operating Expenses was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and -$1.1 million in Q1 2025.